Interview with the Innovators

Identification of new actionable targets and driver mutations have revolutionized the treatment of NSCLC

Waiting for biomarker test results ensures the best outcomes in NSCLC.

Describing the road map of the cancer care journey in NSCLC.

There are an ever-growing number of treatment options that are contributing to more successful outcomes and higher survival rates for cancer patients. The number of care providers that cancer patients need during their journey is also expanding. Please join Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they discuss the role of the multidisciplinary care team approach to deliver the best possible treatment for cancer patients.

Nephrectomy is often the initial treatment for renal-cell cancer (RCC), but systemic therapy is frequently required for advanced RCC. Single-agent targeted therapies are only somewhat effective, which led to the development of immunotherapies and combination therapies (which include immunotherapies). Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss the clinical advantages of combination therapies in patients with advanced RCC.

Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their roles and responsibilities within their academic oncology centers as valuable members of a multidisciplinary team that helps patients successfully navigate the spectrum of patient care. They also detail how they apply the principles of patient-centered care to improve outcomes for patients.

The use of targeted agents and immunotherapy has transformed the treatment of NSCLC

Encouraging shared-decision making by NSCLC by educating and counseling patients and their families

Reflex NGS testing is now the standard of care for many patients with NSCLC